About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker NVAX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 23, 2026Efficacy and Safety of NVX-CoV2705
NCT07086222 · COVID-19, Sars-CoV-2 Infection
NVX-CoV2705, Placebo
NVAX
Novavax
Phase 4Terminated6,500Oct 9, 2026Registry ↗
Jun 5, 2026A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vac…
NCT06291857 · COVID-19
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M…
NVAX
Novavax
Phase 3Completed9,320Dec 24, 2025Registry ↗
Jun 2, 2026Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Respon…
NCT06633835 · COVID-19, Vaccine-Preventable Diseases
protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVI…
NVAX
Novavax
Phase 4Completed660Dec 30, 2024Registry ↗
May 22, 2026Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
NCT05468736 · COVID-19
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Perio…
NVAX
Novavax
Phase 2/3Completed3,600Jan 16, 2024Registry ↗
Apr 17, 2026Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
NCT05463068 · COVID-19, SARS-CoV-2 Infection
NVX-Cov2373
NVAX
Novavax
Phase 3Completed911Aug 17, 2022Registry ↗
Jul 18, 2025A Strain Change Study for SARS-CoV-2 rS Vaccines
NCT06409663 · Severe Acute Respiratory Syndrome Coronavirus 2 Infection
NVX-CoV2705 Vaccine
NVAX
Novavax
Phase 3Completed60Oct 15, 2024Registry ↗
Jul 15, 2025Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
NCT05973006 · COVID-19
NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vac…
NVAX
Novavax
Phase 3Completed400Apr 1, 2024Registry ↗
Jun 26, 2025Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
NCT05875701 · COVID-19
NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant
NVAX
Novavax
Phase 3Completed147Nov 11, 2023Registry ↗
May 8, 2025A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults i…
NCT04583995 · SARS-CoV-2 Infection, COVID-19
SARS-CoV-2 rS/Matrix M1-Adjuvant, Placebo
NVAX
Novavax
Phase 3Completed15,185Mar 29, 2022Registry ↗
May 6, 2025A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal I…
NCT02624947 · Respiratory Syncytial Virus Infections
RSV F vaccine with adjuvant, Formulation buffer
NVAX
Novavax
Phase 3Completed4,636Dec 28, 2018Registry ↗
Apr 10, 2025Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
NCT04961541 · SARS-CoV Infection, Covid19
ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed wit…
NVAX
Novavax
Phase 1/2Completed637Dec 22, 2021Registry ↗
Mar 11, 2025Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine
NCT06485752 · COVID-19
tNIV 1 and Matrix-M Adjuvant
NVAX
Novavax
Phase 2/3Withdrawn0Feb 4, 2025Registry ↗
Mar 11, 2025Lot Consistency Study of COVID-19 and Influenza Combination Vaccine
NCT06482359 · COVID-19, Influenza
coformulated CIC Vaccine, Fluzone HD trivalent
NVAX
Novavax
Phase 2/3Withdrawn0Nov 16, 2025Registry ↗
Dec 13, 2024Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccin…
NCT05925127 · COVID-19
NVX-CoV2373 (5μg), NVX-CoV2601 (5μg)
NVAX
Novavax
Phase 2/3Completed994May 21, 2024Registry ↗
Jul 16, 2024A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
NCT05519839 · COVID-19, Influenza
qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine
NVAX
Novavax
Phase 2Completed1,579Jul 25, 2023Registry ↗
May 30, 2024A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Boost…
NCT05975060 · COVID-19
XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose)
NVAX
Novavax
Phase 2/3Completed660Nov 15, 2023Registry ↗
Apr 23, 2024Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
NCT05372588 · COVID-19, SARS CoV 2 Infection
NVX-CoV2515, NVX-Cov2373
NVAX
Novavax
Phase 3Completed1,340Jul 17, 2022Registry ↗
Dec 21, 2023A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18…
NCT04611802 · SARS-CoV Infection, Covid19
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Perio…
NVAX
Novavax
Phase 3Completed33,000Apr 10, 2023Registry ↗
May 6, 2023Phase 3 Pivotal Trial of NanoFlu™ in Older Adults
NCT04120194 · Influenza, Human
NanoFlu, Fluzone Quadrivalent
NVAX
Novavax
Phase 3Completed2,654Oct 29, 2020Registry ↗
Apr 10, 2023Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Ma…
NCT04368988 · COVID-19
SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant -…
NVAX
Novavax
Phase 1/2Completed1,419Jun 1, 2022Registry ↗
Mar 16, 2023A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Ri…
NCT05112848 · SARS-CoV-2 Infection
NVX-CoV2373
NVAX
Novavax
Phase 2Completed384May 23, 2022Registry ↗
Dec 21, 2022Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vacci…
NCT03293498 · Influenza
NanoFlu, Fluzone HD - Day 0
NVAX
Novavax
Phase 1/2Completed330Mar 14, 2018Registry ↗
Nov 4, 2022Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
NCT03658629 · Influenza, Human
NanoFlu (Quad-NIV), Matrix-M Adjuvant
NVAX
Novavax
Phase 2Terminated1,375Apr 26, 2019Registry ↗
Jul 19, 2022A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults
NCT02608502 · Respiratory Syncytial Virus (RSV)
RSV-F Vaccine, Phosphate Buffer Placebo
NVAX
Novavax
Phase 3Completed11,850Dec 2016Registry ↗
May 31, 2022Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVI…
NCT05029856 · Covid19
SII B.1.351, SII B.1.351
NVAX
Novavax
Phase 1/2Withdrawn0Aug 2022Registry ↗
May 27, 2022Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vac…
NCT02593071 · Respiratory Syncytial Virus (RSV)
RSV-F Vaccine, Phosphate Buffer Placebo
NVAX
Novavax
Phase 2Completed1,330Nov 2016Registry ↗
May 27, 2022Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly…
NCT02266628 · Respiratory Syncytial Virus (RSV)
RSV-F Vaccine, Saline Placebo
NVAX
Novavax
Phase 2Completed1,599Mar 2016Registry ↗
May 27, 2022RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
NCT02247726 · Respiratory Syncytial Virus Infections
Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL inje…
NVAX
Novavax
Phase 2Completed50Jul 2016Registry ↗
Feb 17, 2022A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults
NCT04533399 · SARS-CoV-2 Infection, COVID-19
SARS-CoV-2 rS/Matrix-M1 Adjuvant, Placebo
NVAX
Novavax
Phase 2Completed4,422Dec 7, 2021Registry ↗
Dec 6, 2021Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and…
NCT03026348 · Respiratory Syncytial Viruses
RSV F Vaccine with Aluminum Phosphate Adjuvant, RSV F Vacci…
NVAX
Novavax
Phase 2Completed300Apr 2017Registry ↗
Nov 24, 2021Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine…
NCT02370589 · Ebola
Base Dose EBOV GP Vaccine, 2x Base Dose EBOV GP Vaccine
NVAX
Novavax
Phase 1Completed230Apr 2016Registry ↗
Sep 23, 2016Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
NCT02307851 · Influenza
Quadrivalent VLP Vaccine, Comparator TIV
NVAX
Novavax
Phase 2Completed400Jun 2015Registry ↗
Sep 23, 2016A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant
NCT02078674 · Influenza (Pandemic)
Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant
NVAX
Novavax
Phase 1/2Completed610Jul 2015Registry ↗
May 26, 2016RSV F Dose-Ranging Study in Women
NCT01960686 · Respiratory Syncytial Virus Infections
Low dose RSV F Antigen, High dose RSV F Antigen
NVAX
Novavax
Phase 2Completed720Apr 2014Registry ↗
Apr 28, 2016A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of…
NCT02296463 · Respiratory Synctial Virus
RSV F Vaccine with adjuvant (0.5mL injection), RSV F Vaccin…
NVAX
Novavax
Phase 1Completed32Sep 2015Registry ↗

35 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 10:47 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances